Cargando…
Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
BACKGROUND: A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficac...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935149/ https://www.ncbi.nlm.nih.gov/pubmed/31881856 http://dx.doi.org/10.1186/s12885-019-6475-6 |
_version_ | 1783483529189916672 |
---|---|
author | Kotani, Daisuke Kuboki, Yasutoshi Horasawa, Satoshi Kaneko, Asumi Nakamura, Yoshiaki Kawazoe, Akihito Bando, Hideaki Taniguchi, Hiroya Shitara, Kohei Kojima, Takashi Tsuji, Akihito Yoshino, Takayuki |
author_facet | Kotani, Daisuke Kuboki, Yasutoshi Horasawa, Satoshi Kaneko, Asumi Nakamura, Yoshiaki Kawazoe, Akihito Bando, Hideaki Taniguchi, Hiroya Shitara, Kohei Kojima, Takashi Tsuji, Akihito Yoshino, Takayuki |
author_sort | Kotani, Daisuke |
collection | PubMed |
description | BACKGROUND: A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings. METHODS: Records of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution. RESULTS: Totally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3–5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8–2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48–0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444). CONCLUSIONS: In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities. TRIAL REGISTRATION: Retrospectively registered. |
format | Online Article Text |
id | pubmed-6935149 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-69351492019-12-30 Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer Kotani, Daisuke Kuboki, Yasutoshi Horasawa, Satoshi Kaneko, Asumi Nakamura, Yoshiaki Kawazoe, Akihito Bando, Hideaki Taniguchi, Hiroya Shitara, Kohei Kojima, Takashi Tsuji, Akihito Yoshino, Takayuki BMC Cancer Research Article BACKGROUND: A previous phase I/II C-TASK FORCE study of trifluridine/tipiracil plus bevacizumab for patients with heavily pretreated metastatic colorectal cancer (mCRC) showed promising activity with an acceptable toxicity profile. This retrospective study aimed to investigate the safety and efficacy of trifluridine/tipiracil plus bevacizumab compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC in clinical settings. METHODS: Records of patients with mCRC refractory to standard therapies who initiated trifluridine/tipiracil plus bevacizumab from January 2016 to March 2018 or trifluridine/tipiracil monotherapy from June 2014 to December 2015 were retrospectively reviewed at our institution. RESULTS: Totally, 60 patients received trifluridine/tipiracil plus bevacizumab and 66 received trifluridine/tipiracil monotherapy. All patients had previously received standard chemotherapy. Median progression-free survival (PFS) was 3.7 months [95% confidence interval (CI), 2.3–5.1] in the trifluridine/tipiracil plus bevacizumab group and 2.2 months (95% CI, 1.8–2.6) in the trifluridine/tipiracil monotherapy group [hazards ratio (HR) 0.69; 95% CI 0.48–0.99]. PFS rate at 16 weeks was 46.6% for the trifluridine/tipiracil plus bevacizumab group and 33.9% for the trifluridine/tipiracil monotherapy group. Although a relatively higher incidence of grade ≥ 3 neutropenia was observed in the trifluridine/tipiracil plus bevacizumab group than that in the other group (50.0% vs. 40.9%, p = 0.371), the incidence of febrile neutropenia was not high (3.3% vs. 7.8%, p = 0.444). CONCLUSIONS: In real-world settings, trifluridine/tipiracil plus bevacizumab prolonged PFS and helped achieve higher 16-week PFS rate compared with trifluridine/tipiracil monotherapy in patients with heavily pretreated mCRC with manageable toxicities. TRIAL REGISTRATION: Retrospectively registered. BioMed Central 2019-12-27 /pmc/articles/PMC6935149/ /pubmed/31881856 http://dx.doi.org/10.1186/s12885-019-6475-6 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Kotani, Daisuke Kuboki, Yasutoshi Horasawa, Satoshi Kaneko, Asumi Nakamura, Yoshiaki Kawazoe, Akihito Bando, Hideaki Taniguchi, Hiroya Shitara, Kohei Kojima, Takashi Tsuji, Akihito Yoshino, Takayuki Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title_full | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title_fullStr | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title_full_unstemmed | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title_short | Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
title_sort | retrospective cohort study of trifluridine/tipiracil (tas-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6935149/ https://www.ncbi.nlm.nih.gov/pubmed/31881856 http://dx.doi.org/10.1186/s12885-019-6475-6 |
work_keys_str_mv | AT kotanidaisuke retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT kubokiyasutoshi retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT horasawasatoshi retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT kanekoasumi retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT nakamurayoshiaki retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT kawazoeakihito retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT bandohideaki retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT taniguchihiroya retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT shitarakohei retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT kojimatakashi retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT tsujiakihito retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer AT yoshinotakayuki retrospectivecohortstudyoftrifluridinetipiraciltas102plusbevacizumabversustrifluridinetipiracilmonotherapyformetastaticcolorectalcancer |